The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis

SIMPLE SUMMARY: Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with chemotherapy and immunotherapy. In this report, we looked at the extent of EV wastage (i.e., discarding of leftover drug not administered to the patient) in a single institute a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarfaty, Michal, Moore, Assaf, Regazzi, Ashley M., Mitchell, Aaron P., Rosenberg, Jonathan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657095/
https://www.ncbi.nlm.nih.gov/pubmed/34885086
http://dx.doi.org/10.3390/cancers13235977

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657095/
https://www.ncbi.nlm.nih.gov/pubmed/34885086
http://dx.doi.org/10.3390/cancers13235977

Ejemplares similares